Viewing Study NCT01946568

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 5:29 PM

Ignite Modification Date: 2026-01-06 @ 4:38 AM

Study NCT ID: NCT01946568

Status: COMPLETED

Last Update Posted: 2015-06-23

First Post: 2013-08-29

Is Gene Therapy: True

Has Adverse Events: False

Brief Title: A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module